Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients

Circulation Journal

Volumn 74, Issue 5, 2010, Pages 977-982

  Takeuchi, Fumihiko ^a   Kashida, Mitsuo ^a   Okazaki, Osamu ^a   Tanaka, Yuriko ^a   Fukuda, Shoji ^a   Kashima, Toshitaka ^a   Hosaka, Shigeru ^a   Hiroe, Michiaki ^a   Kimura, Sosuke ^a   Kato, Norihiro ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Anticoagulation; CYP2C9; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

AMIODARONE; CARBAMAZEPINE; PHENYTOIN; RIFAMPICIN; WARFARIN;

ACCURACY; AGED; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ARTICLE; CIGARETTE SMOKING; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GENETIC ALGORITHM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAPANESE; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS;

AGED; ALCOHOL DRINKING; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SMOKING; WARFARIN;

EID: 77951719226     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0876     Document Type: Article

References (31)

1. Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-1711.
2. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-233S.
3. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008; 25: 45-51.
4. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: Comparison with other equations. Pharmacogenomics 2008; 9: 169-178.
5. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101-110.
6. Poller L, Shiach CR, MacCallum PK, Johansen AM, Münster AM, Magalhães A, et al. Multicentre randomised study of computerised anticoagulant dosage: European Concerted Action on Anticoagulation. Lancet 1998; 352: 1505-1509.
7. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
8. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
9. Gan GG, Teh A, Goh KY, Chong HT, Pang KW. Racial background is a determinant factor in the maintenance dosage of warfarin. Int J Hematol 2003; 78: 84-86.
10. Suzuki S, Yamashita T, Kato T, Fujino T, Sagara K, Sawada H, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 2007; 71: 761-765.
11. Kimura M, Wasaki Y, Ogawa H, Nakatsuka M, Wakeyama T, Iwami T, et al. Effect of low-intensity warfarin therapy on left atrial thrombus resolution in patients with nonvalvular atrial fibrillation: A transesophageal echocardiographic study. Jpn Circ J 2001; 65: 271-274.
12. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group; Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: A multicenter, prospective, randomized trial. Stroke 2000; 31: 817-821.
13. Matsuyama K, Matsumoto M, Sugita T, Nishizawa J, Yoshida K, Tokuda Y, et al. Anticoagulant therapy in Japanese patients with mechanical mitral valves. Circ J 2002; 66: 668-670.
14. Takeuchi F, Serizawa M, Yamamoto K, Fujisawa T, Nakashima E, Ohnaka K, et al. Confirmation of multiple risk loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. Diabetes 2009; 58: 1690-1699.
15. Mushiroda T, Ohnishi Y, Saito S, Takahashi A, Kikuchi Y, Saito S, et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 2006; 51: 249-253.
16. Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-263.
17. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120: 181-186.
18. Ohno M, Yamamoto A, Ono A, Miura G, Funamoto M, Takemoto Y, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol 2009; 65: 1097-1103.
19. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-355.
20. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-539.
21. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
22. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
23. Torn M, Cannegieter SC, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: A prospective study of 4202 patients. Arch Intern Med 2009; 169: 1203-1209.
24. Miyazaki S, Kuwahara T, Takahashi A, Kobori A, Takahashi Y, Nozato T, et al. Effect of left atrial ablation on the quality of life in patients with atrial fibrillation. Circ J 2008; 72: 582-587.
25. Ogawa H, Ishikawa T, Matsushita K, Matsumoto K, Ishigami T, Sugano T, et al. Effects of right atrial pacing preference in prevention of paroxysmal atrial fibrillation: Atrial Pacing Preference study (APP study). Circ J 2008; 72: 700-704.
26. Furusho H, Takamura M, Takata S, Sakagami S, Hirazawa M, Kato T, et al. Current status of anticoagulation therapy for elderly atrial fibrillation patients in Japan: From Hokuriku atrial fibrillation trial. Circ J 2008; 72: 2058-2061.
27. The Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008). Circ J 2008; 72(Suppl IV): 1581-1658 (in Japanese).
28. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-1027.
29. Krynetskiy E, McDonnell P. Building individualized medicine: Prevention of adverse reactions to warfarin therapy. J Pharmacol Exp Ther 2007; 322: 427-434.
30. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433.
31. Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med 2009; 151: 270-273, W95.